================================================================================
CLINICAL TRIALS MATCHES REPORT (STUDIES WITH PUBLICATIONS AND POSTED RESULTS ONLY)
================================================================================

Patient ID: 2
Diagnosis: NET des Dünndarms mit Lymphknoten und Lebermetastasen (ED 2015)
Koloskopie bei unklaren abdominellen Beschwerden 06/2015: Tumor im Ileum 25 cm oberhalb der Ileozökalklappe. G3 NET, Ki67 48%.
07/2015 CT staging Thorax/Abdomen: Primärtumor des Ileums 40 x 40 x 70 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.

07/2015 Hemicolektomie rechts und Ileumteilresektion mit Lymphadenektomie.
Clinical Question: Weitere Therapie?
Report generated: 2025-07-15 14:08:01

Found 15 relevant clinical trials (with publications and posted results)
--------------------------------------------------------------------------------

1. Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
   NCT ID: NCT02441062
   Status: COMPLETED
   Phase: PHASE2
   Clinically Relevant: YES (Score: 1.0)
   Relevance Reason: 
## NET Clinical Trial Evaluation

**DECISION: YES**

**REASONING:**

1. **Diagnostic Relevance:** The study explicitly targets patients with histologically proven neuroendocrine tumors (NETs), which ...
   Has Posted Results: YES (verified)
   Condition: Neuroendocrine Tumors; Carcinoid Tumors; Neuroblastoma; Medulloblastoma
   Intervention: 68Ga-DOTATOC PET/CT
   Sponsor: Sue O'Dorisio
   Start Date: 2015-09
   Completion Date: 2020-01-20
   Locations: University of Iowa Hospitals and Clinics, Iowa City, United States
   URL: https://clinicaltrials.gov/study/NCT02441062
   Summary: Participants in this study have been diagnosed with a tumor such as a carcinoid, neuroendocrine tumor, neuroblastoma, Ewing's sarcoma, or brain tumor that has cells which carry somatostatin receptors.

The purpose of this research study is to see if the tumor can be identified using a special proced...
   Publications Found: 1
     1. Menda Y, Ponto LL, Schultz MK, Zamba GK, Watkins GL, Bushnell DL, Madsen MT, Sunderland JJ, Graham M... (N/A)
        PMID: 23587853 | Journal: From Clinical Trial Data
        Link: https://pubmed.ncbi.nlm.nih.gov/23587853/
----------------------------------------

2. Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
   NCT ID: NCT02709889
   Status: TERMINATED
   Phase: PHASE1
   Clinically Relevant: YES (Score: 1.0)
   Relevance Reason: ## NET Clinical Trial Evaluation - Rovalpituzumab Tesirine

**DECISION: YES**

**REASONING:**

1. **Diagnostic Relevance:** The study explicitly includes “high-grade gastroenteropancreatic neuroendocr...
   Has Posted Results: YES (verified)
   Condition: Malignant Melanoma; Medullary Thyroid Cancer; Glioblastoma; Large-Cell Neuroendocrine Carcinoma; Neuroendocrine Prostate Cancer; High Grade Gastroenteropancreatic Neuroendocrine Carcinoma; Other Neuroendocrine Carcinoma; Other Solid Tumors
   Intervention: Rovalpituzumab tesirine; Dexamethasone
   Sponsor: AbbVie
   Start Date: 2016-09-23
   Completion Date: 2019-08-27
   Locations: Banner MD Anderson Cancer Ctr /ID# 155424, Gilbert, United States; Mayo Clinic - Scottsdale /ID# 155419, Scottsdale, United States; University of California, Los Angeles /ID# 155429, Los Angeles, United States
   URL: https://clinicaltrials.gov/study/NCT02709889
   Summary: The primary objective of this study is to assess the safety and tolerability of rovalpituzumab tesirine in subjects with specific delta-like protein 3-expressing advanced solid tumors.
   Publications Found: 2
     1. Xie H, Kaye FJ, Isse K, Sun Y, Ramoth J, French DM, Flotte TJ, Luo Y, Saunders LR, Mansfield AS. Del... (N/A)
        PMID: 32372416 | Journal: From Clinical Trial Data
        Link: https://pubmed.ncbi.nlm.nih.gov/32372416/
     2. A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. (2021)
        PMID: 34354225 | Journal: NPJ precision oncology
        DOI: 10.1038/s41698-021-00214-y
        Link: https://pubmed.ncbi.nlm.nih.gov/34354225/
----------------------------------------

3. PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
   NCT ID: NCT03365791
   Status: COMPLETED
   Phase: PHASE2
   Clinically Relevant: YES (Score: 1.0)
   Relevance Reason: 
## NET Clinical Trial Evaluation

**DECISION:** YES

**REASONING:**

1. **Diagnostic Relevance:** The study explicitly includes “Advanced well-differentiated neuroendocrine tumors” as one of its seve...
   Has Posted Results: YES (verified)
   Condition: Small Cell Lung Cancer; Gastric Adenocarcinoma; Esophageal Adenocarcinoma; Castration Resistant Prostate Adenocarcinoma; Soft Tissue Sarcoma; Ovarian Adenocarcinoma; Advanced Well-differentiated Neuroendocrine Tumors; Diffuse Large B Cell Lymphoma
   Intervention: PDR001; LAG525
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2018-01-24
   Completion Date: 2020-09-17
   Locations: California Pacific Medical Center Drug Shipment (2), San Francisco, United States; Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, United States; University Cancer and Blood Center, LLC, Athens, United States
   URL: https://clinicaltrials.gov/study/NCT03365791
   Summary: The purpose of this signal seeking study is to determine whether treatment with PDR001 and LAG525 demonstrates sufficient efficacy in advanced malignancies to warrant further study.
   Publications: No publications found
----------------------------------------

4. Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
   NCT ID: NCT01970540
   Status: COMPLETED
   Phase: PHASE1
   Clinically Relevant: YES (Score: 1.0)
   Relevance Reason: 
## NET Clinical Trial Evaluation

**DECISION: YES**

**REASONING:**

1. **Diagnostic Relevance:** The study *specifically* includes neuroendocrine tumors (NETs) in its expansion cohort, making it hig...
   Has Posted Results: YES (verified)
   Condition: Endometrial Adenocarcinomas; Neuroendocrine Tumors; Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy
   Intervention: lurbinectedin (PM01183); Doxorubicin
   Sponsor: PharmaMar
   Start Date: 2011-05-25
   Completion Date: 2017-08-09
   Locations: Hospital Universitari Vall D'Hebron, Barcelona, Spain; Centro Oncológico Md Anderson International España, Madrid, Spain; Hospital Ramón Y Cajal, Madrid, Spain
   URL: https://clinicaltrials.gov/study/NCT01970540
   Summary: Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination with Fixed Doxorubicin in Non- Heavily Pretreated Patients with Selected Advanced Solid Tumors to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM01183 in combination with doxo...
   Publications Found: 1
     1. Olmedo ME, Forster M, Moreno V, Lopez-Criado MP, Brana I, Flynn M, Doger B, de Miguel M, Lopez-Vilar... (N/A)
        PMID: 33704620 | Journal: From Clinical Trial Data
        Link: https://pubmed.ncbi.nlm.nih.gov/33704620/
----------------------------------------

5. Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
   NCT ID: NCT00610129
   Status: COMPLETED
   Phase: PHASE2
   Clinically Relevant: YES (Score: 1.0)
   Relevance Reason: ## NET Clinical Trial Evaluation - MK-0646 in Metastatic NETs

**DECISION: YES**

**REASONING:**

1. **Diagnostic Relevance:** The study explicitly targets patients with *Metastatic Neuroendocrine Tum...
   Has Posted Results: YES (verified)
   Condition: Neuroendocrine Tumors; Metastatic Neuroendocrine Tumors
   Intervention: MK-0646
   Sponsor: Memorial Sloan Kettering Cancer Center
   Start Date: 2008-01
   Completion Date: 2010-01
   Locations: Memorial Sloan-Kettering at Basking Ridge, Basking Ridge, United States; Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack, United States; Memorial Sloan-Kettering Cancer Center, New York, United States
   URL: https://clinicaltrials.gov/study/NCT00610129
   Summary: The purpose of this study is to test a new drug for neuroendocrine tumors. We think that this new drug may help control your tumor.

MK-0646 is a monoclonal antibody. An antibody is a protein that is able to attach to specific target on cancer cells. This target helps the cancer cells grow and divid...
   Publications: No publications found
----------------------------------------

6. Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin
   NCT ID: NCT02420691
   Status: COMPLETED
   Phase: PHASE2
   Clinically Relevant: YES (Score: 1.0)
   Relevance Reason: 

## NET Clinical Trial Evaluation

**DECISION: YES**

**REASONING:**

1. **Diagnostic Relevance:** The study focuses on advanced neuroendocrine tumors (NETs) of foregut origin. The patient has a NET ...
   Has Posted Results: YES (verified)
   Condition: Advanced Digestive System Neuroendocrine Neoplasm; Duodenal Neuroendocrine Tumor G1; Functional Pancreatic Neuroendocrine Tumor; Gastric Neuroendocrine Tumor; Intermediate Grade Lung Neuroendocrine Neoplasm; Low Grade Lung Neuroendocrine Neoplasm; Nonfunctional Pancreatic Neuroendocrine Tumor; Thymus Neoplasm
   Intervention: Laboratory Biomarker Analysis; Pharmacological Study; Ribociclib
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2015-08-25
   Completion Date: 2019-06-05
   Locations: M D Anderson Cancer Center, Houston, United States
   URL: https://clinicaltrials.gov/study/NCT02420691
   Summary: This phase II trial studies how well ribociclib works in treating patients with neuroendocrine tumors of the foregut, which includes the thymus, lung, stomach, and pancreas, that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced tumors). Riboc...
   Publications: No publications found
----------------------------------------

7. Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)
   NCT ID: NCT01524783
   Status: COMPLETED
   Phase: PHASE3
   Clinically Relevant: YES (Score: 1.0)
   Relevance Reason: 

## NET Clinical Trial Evaluation

**DECISION: YES**

**REASONING:**

1. **Diagnostic Relevance:** The study explicitly targets advanced Neuroendocrine Tumors (NETs) of GI or lung origin. This patien...
   Has Posted Results: YES (verified)
   Condition: Advanced NET of GI Origin; Advanced NET of Lung Origin; Neuroendocrine Tumors
   Intervention: Everolimus; Placebo; Best suportive care (BSC)
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2012-03-30
   Completion Date: 2020-08-07
   Locations: University of California San Diego - Moores Cancer Center Regulatory, La Jolla, United States; Scripps Clinic Regulatory, La Jolla, United States; Cedars Sinai Medical Center SC, Los Angeles, United States
   URL: https://clinicaltrials.gov/study/NCT01524783
   Summary: The purpose of this study is to compare the antitumor activity of everolimus plus best supportive care versus placebo plus best supportive care in patients with progressive nonfunctional neuroendocrine tumor (NET) of gastrointestinal (GI) or lung origin without a history of, or current symptoms of c...
   Publications Found: 5
     1. Chan DL, Yao JC, Carnaghi C, Buzzoni R, Herbst F, Ridolfi A, Strosberg J, Kulke MH, Pavel M, Singh S... (N/A)
        PMID: 33560090 | Journal: From Clinical Trial Data
        Link: https://pubmed.ncbi.nlm.nih.gov/33560090/
     2. Buzzoni R, Carnaghi C, Strosberg J, Fazio N, Singh S, Herbst F, Ridolfi A, Pavel ME, Wolin EM, Valle... (N/A)
        PMID: 29081664 | Journal: From Clinical Trial Data
        Link: https://pubmed.ncbi.nlm.nih.gov/29081664/
     3. Fazio N, Buzzoni R, Delle Fave G, Tesselaar ME, Wolin E, Van Cutsem E, Tomassetti P, Strosberg J, Vo... (N/A)
        PMID: 29055056 | Journal: From Clinical Trial Data
        Link: https://pubmed.ncbi.nlm.nih.gov/29055056/
----------------------------------------

8. TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
   NCT ID: NCT01677910
   Status: COMPLETED
   Phase: PHASE3
   Clinically Relevant: YES (Score: 1.0)
   Relevance Reason: ## TELESTAR Study Evaluation – NET Patient

**DECISION: YES**

**REASONING:**

1. **Diagnostic Relevance:** The study targets patients with carcinoid syndrome, which is a common manifestation of neuro...
   Has Posted Results: YES (verified)
   Condition: Carcinoid Syndrome
   Intervention: Telotristat etiprate; Placebo-matching telotristat etiprate
   Sponsor: Lexicon Pharmaceuticals
   Start Date: 2013-01-08
   Completion Date: 2016-03-21
   Locations: Lexicon Investigational Site, Mobile, United States; Lexicon Investigational Site, Palo Alto, United States; Lexicon Investigational Site, San Francisco, United States
   URL: https://clinicaltrials.gov/study/NCT01677910
   Summary: The primary objective of the study is to confirm that at least 1 or more doses of telotristat etiprate compared to placebo is effective in reducing the number of daily bowel movements (BMs) from baseline averaged over the 12-week double-blind portion (Treatment Period) of the trial in patients not a...
   Publications Found: 6
     1. Srirajaskanthan R, Pavel M, Kulke M, Clement D, Houchard A, Keeber L, Weickert MO. Weight Maintenanc... (N/A)
        PMID: 34598813 | Journal: From Clinical Trial Data
        Link: https://pubmed.ncbi.nlm.nih.gov/34598813/
     2. Fust K, Maschio M, Kohli M, Singh S, Pritchard DM, Marteau F, Myrenfors P, Feuilly M. A Budget Impac... (N/A)
        PMID: 32157590 | Journal: From Clinical Trial Data
        Link: https://pubmed.ncbi.nlm.nih.gov/32157590/
     3. Dillon JS, Kulke MH, Horsch D, Anthony LB, Warner RRP, Bergsland E, Welin S, O'Dorisio TM, Kunz PL, ... (N/A)
        PMID: 32146619 | Journal: From Clinical Trial Data
        Link: https://pubmed.ncbi.nlm.nih.gov/32146619/
----------------------------------------

9. Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
   NCT ID: NCT01782443
   Status: COMPLETED
   Phase: PHASE2
   Clinically Relevant: YES (Score: 1.0)
   Relevance Reason: 

## NET Clinical Trial Evaluation

**DECISION: YES**

**REASONING:**

1. **Diagnostic Relevance:** The study specifically targets “Advanced Progressive Carcinoid Tumors”. While the description doesn’...
   Has Posted Results: YES (verified)
   Condition: Carcinoid Tumor
   Intervention: Ziv-aflibercept
   Sponsor: Dana-Farber Cancer Institute
   Start Date: 2013-02-13
   Completion Date: 2021-12-26
   Locations: Massachusetts General Hospital, Boston, United States; Brigham and Women's Hospital, Boston, United States; Dana-Farber Cancer Institute, Boston, United States
   URL: https://clinicaltrials.gov/study/NCT01782443
   Summary: This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer. "Investigational" means that the drug, Ziv-aflibercept, is being studied. It also means that the FDA has not yet approv...
   Publications Found: 1
     1. Perez K, Kulke MH, Horick NK, Regan E, Graham C, Scheutz S, Stonely D, Enzinger PC, Fuchs CS, Allen ... (N/A)
        PMID: 36395401 | Journal: From Clinical Trial Data
        Link: https://pubmed.ncbi.nlm.nih.gov/36395401/
----------------------------------------

10. Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
   NCT ID: NCT01327612
   Status: COMPLETED
   Phase: PHASE2
   Clinically Relevant: YES (Score: 1.0)
   Relevance Reason: ## NET Clinical Trial Evaluation - Conatumumab & Ganitumab

**DECISION: YES**

**REASONING:**

1. **Diagnostic Relevance:** The study doesn’t explicitly state NET inclusion, focusing on solid tumors. ...
   Has Posted Results: YES (verified)
   Condition: Advanced Solid Tumors; Carcinoid; Colorectal Cancer; Locally Advanced; Lymphoma; Metastatic Cancer; Non-Small Cell Lung Cancer; Sarcoma; Solid Tumors
   Intervention: Modified FOLFOX6; Conatumumab; Ganitumab; Bevacizumab
   Sponsor: Amgen
   Start Date: 2011-03-03
   Completion Date: 2020-02-05
   Locations: Research Site, Duarte, United States; Research Site, La Jolla, United States; Research Site, Denver, United States
   URL: https://clinicaltrials.gov/study/NCT01327612
   Summary: The purpose of this protocol is to allow continued treatment with conatumumab and/or ganitumab, with or without chemotherapy, to participants who completed a separate Amgen-sponsored conatumumab or ganitumab study without disease progression whose previous studies were closed.
   Publications: No publications found
----------------------------------------

11. Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease
   NCT ID: NCT00690430
   Status: COMPLETED
   Phase: PHASE3
   Clinically Relevant: YES (Score: 1.0)
   Relevance Reason: ## NET Clinical Trial Evaluation

**PATIENT PROFILE SUMMARY:** Patient has metastatic small bowel NET (ileum), diagnosed in 2015, with lymph node and liver metastases. Tumor is G3 with a high Ki67 of ...
   Has Posted Results: YES (verified)
   Condition: Symptomatic Refractory Resistant Carcinoid Disease
   Intervention: Pasireotide; Octreotide
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2008-04
   Completion Date: 2012-04
   Locations: Scottsdale Healthcare/TGen Clinical Research Service TGen Clinical Research Service, Scottsdale, United States; University of Arizona / Arizona Cancer Center, Tucson, United States; Loma Linda University Dept. of Loma Linda CancerCent, Loma Linda, United States
   URL: https://clinicaltrials.gov/study/NCT00690430
   Summary: The purpose of this randomized, multicenter, Phase III study was to compare the efficacy of paseriotide LAR and octreotide LAR in patients whose disease-related symptoms are inadequately controlled by currently available somatostatin analogues.
   Publications: No publications found
----------------------------------------

12. A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
   NCT ID: NCT01578239
   Status: COMPLETED
   Phase: PHASE3
   Clinically Relevant: YES (Score: 1.0)
   Relevance Reason: 

## NET Clinical Trial Evaluation

**DECISION: YES**

**REASONING:**

1. **Diagnostic Relevance:** The study specifically targets midgut carcinoid tumors, which is precisely the type of NET this pati...
   Has Posted Results: YES (verified)
   Condition: Carcinoid Tumor of the Small Bowel; Neuroendocrine Tumour
   Intervention: Octreotide LAR; 177Lu-DOTA0-Tyr3-Octreotate
   Sponsor: Advanced Accelerator Applications
   Start Date: 2012-09-06
   Completion Date: 2021-01-18
   Locations: Cedars-Sinai Medical Center Samuel Oschin Cancer Center, Los Angeles, United States; Stanford Cancer Center, Palo Alto, United States; Moffitt Cancer Center, Tampa, United States
   URL: https://clinicaltrials.gov/study/NCT01578239
   Summary: This was a multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with Lutathera plus best supportive care (30 mg Octreotide LAR) to treatment with high dose (60 mg) Octreotide LAR in participants with metastasized or locally advanced, in...
   Publications Found: 4
     1. Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, P... (N/A)
        PMID: 34793718 | Journal: From Clinical Trial Data
        Link: https://pubmed.ncbi.nlm.nih.gov/34793718/
     2. Strosberg J, Kunz PL, Hendifar A, Yao J, Bushnell D, Kulke MH, Baum RP, Caplin M, Ruszniewski P, Del... (N/A)
        PMID: 32123969 | Journal: From Clinical Trial Data
        Link: https://pubmed.ncbi.nlm.nih.gov/32123969/
     3. Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday T, Hendifar A... (N/A)
        PMID: 29878866 | Journal: From Clinical Trial Data
        Link: https://pubmed.ncbi.nlm.nih.gov/29878866/
----------------------------------------

13. An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
   NCT ID: NCT00774930
   Status: COMPLETED
   Phase: PHASE3
   Clinically Relevant: YES (Score: 1.0)
   Relevance Reason: ## NET Clinical Trial Eligibility Evaluation

**DECISION:** YES

**REASONING:**

1. **Diagnostic Relevance:** The study targets patients with carcinoid syndrome, which is a common manifestation of neu...
   Has Posted Results: YES (verified)
   Condition: Carcinoid Syndrome
   Intervention: Lanreotide; Placebo
   Sponsor: Ipsen
   Start Date: 2009-05
   Completion Date: 2015-12
   Locations: VA Greater Los Angeles Health Care System, Los Angeles, United States; David Geffen School of Medicine at UCLA, Los Angeles, United States; Stanford Cancer Center, Stanford, United States
   URL: https://clinicaltrials.gov/study/NCT00774930
   Summary: The purpose of this study was to determine whether monthly deep subcutaneous (s.c.) injections of lanreotide Autogel (Somatuline Depot) were effective and safe in controlling diarrhoea and flushing by reducing the usage of s.c. short-acting octreotide as a rescue medication to control symptoms in su...
   Publications Found: 2
     1. Vinik AI, Wolin EM, Liyanage N, Gomez-Panzani E, Fisher GA; ELECT Study Group *. EVALUATION OF LANRE... (N/A)
        PMID: 27214300 | Journal: From Clinical Trial Data
        Link: https://pubmed.ncbi.nlm.nih.gov/27214300/
     2. Blot K, Duchateau L, Lescrauwaet B, Liyanage N, Ray D, Mirakhur B, Vinik AI. A Patient-Reported Outc... (N/A)
        PMID: 31754316 | Journal: From Clinical Trial Data
        Link: https://pubmed.ncbi.nlm.nih.gov/31754316/
----------------------------------------

14. Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome
   NCT ID: NCT01104415
   Status: COMPLETED
   Phase: PHASE2
   Clinically Relevant: YES (Score: 1.0)
   Relevance Reason: 
## NET Clinical Trial Evaluation

**PATIENT PROFILE SUMMARY:** Patient has a G3 midgut neuroendocrine tumor (NET) of the small intestine (ileum) diagnosed in 2015, with lymph node and liver metastase...
   Has Posted Results: YES (verified)
   Condition: Carcinoid Syndrome
   Intervention: Telotristat etiprate
   Sponsor: Lexicon Pharmaceuticals
   Start Date: 2010-06-15
   Completion Date: 2014-02-12
   Locations: Lexicon Investigational Site, Bad Berka, Germany; Lexicon Investigational Site, Berlin, Germany; Lexicon Investigational Site, Halle, Germany
   URL: https://clinicaltrials.gov/study/NCT01104415
   Summary: The purpose of the study is to evaluate the safety and tolerability of orally administered telotristat etiprate (LX1606) in participants with symptomatic carcinoid syndrome.
   Publications Found: 1
     1. Pavel M, Horsch D, Caplin M, Ramage J, Seufferlein T, Valle J, Banks P, Lapuerta P, Sands A, Zambrow... (N/A)
        PMID: 25636046 | Journal: From Clinical Trial Data
        Link: https://pubmed.ncbi.nlm.nih.gov/25636046/
----------------------------------------

15. Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors
   NCT ID: NCT00510068
   Status: COMPLETED
   Phase: PHASE3
   Clinically Relevant: YES (Score: 1.0)
   Relevance Reason: ## NET Clinical Trial Evaluation

**PATIENT PROFILE SUMMARY:** Patient has a G3 midgut NET (small bowel, ileum) diagnosed in 2015 with lymph node and liver metastases. They underwent surgical resectio...
   Has Posted Results: YES (verified)
   Condition: Advanced Neuroendocrine Tumors of Pancreatic Origin
   Intervention: Everolimus; Everolimus Placebo
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2007-07
   Completion Date: 2014-03
   Locations: University of South Alabama / Mitchell Cancer Institute Deptof Mitchell Cancer Inst(2), Mobile, United States; Pacific Cancer Medical Center, Inc., Anaheim, United States; Cedars Sinai Medical Center SC-2, Los Angeles, United States
   URL: https://clinicaltrials.gov/study/NCT00510068
   Summary: The purpose of this study was to evaluate progression free survival in those participants assigned everolimus 10 mg/day plus Best Supportive Care versus those assigned to placebo plus Best Supportive Care in Advanced Neuroendocrine Tumors of pancreatic origin.
   Publications Found: 5
     1. Chan DL, Yao JC, Carnaghi C, Buzzoni R, Herbst F, Ridolfi A, Strosberg J, Kulke MH, Pavel M, Singh S... (N/A)
        PMID: 33560090 | Journal: From Clinical Trial Data
        Link: https://pubmed.ncbi.nlm.nih.gov/33560090/
     2. Yao JC, Voi M, Lincy J, Pavel M. Reply to V. Amoroso et al. J Clin Oncol. 2017 May 1;35(13):1488-148... (N/A)
        PMID: 28113028 | Journal: From Clinical Trial Data
        Link: https://pubmed.ncbi.nlm.nih.gov/28113028/
     3. Yao JC, Pavel M, Lombard-Bohas C, Van Cutsem E, Voi M, Brandt U, He W, Chen D, Capdevila J, de Vries... (N/A)
        PMID: 27621394 | Journal: From Clinical Trial Data
        Link: https://pubmed.ncbi.nlm.nih.gov/27621394/
----------------------------------------